Alpha-1-antitrypsin gene therapy-inhalation (Aradigm/geneRx+)

N/A

Report date: 2022/01/14 13:23:58

Base Information

Drug NameAlpha-1-antitrypsin gene therapy-inhalation (Aradigm/geneRx+)
Drug Alias Nameα1抗胰蛋白酶基因疗法(Aradigm/geneRx+)AlphagenAAT deficiency gene therapy
ClassificationCell and gene therapy > Gene therapy
Mechanisms of ActionTrypsin inhibitors
TargetsTrypsin
Therapy Area/IndicationsPulmonary Disease, Chronic Obstructivealpha 1-Antitrypsin Deficiency
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryN/A
CombinationsNo
Global Highest StatusDiscontinued (Phase 1 Clinical)
Highest Status in ChinaN/A
Originator CompaniesGenerx+Aradigm
China Registration ClassN/A

Develop Information

Active CompaniesN/A
Inactive CompaniesAradigmGenerx+
Active IndicationsN/A
Inactive IndicationsPulmonary Disease, Chronic Obstructivealpha 1-Antitrypsin Deficiency

Other Information

ATC CodeN/A
Related LinksN/A